• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The assessment of the intrasubject variability in digoxin absorption in man from two oral dosage forms.

作者信息

Yacobi A, Stoll R G, Chao G C, Schwartz R A, Weidler D J, Ayers J W, Sakmar E, Hallmark M, Wagner J G

出版信息

J Clin Pharmacol. 1981 Jul;21(7):301-10. doi: 10.1002/j.1552-4604.1981.tb01771.x.

DOI:10.1002/j.1552-4604.1981.tb01771.x
PMID:7263929
Abstract

The reproducibility of drug absorption within a given subject as well as the evaluation of bioavailability of two digoxin dosage forms were studied. The data showed (a) a higher initial plasma digoxin concentration after the soft elastic gelatin (SEG) capsule; (b) a more irregular absorption after the tablet; (c) on the average, the coefficients of variation of individual plasma concentrations were lower after the capsule; and (d) for the capsule, the intrasubject variations of the peak plasma concentrations, time of peak, area under plasma concentrations-versus-time curve (AUC), and amount digoxin excreted in urine (Ae) were on the average 60 per cent of the variations in the tablet parameters. The ratios of AUC and Ae for capsule/tablet were essentially unity, indicating that the amount digoxin absorbed from the 0.4-mg digoxin SEG capsule is identical to that from a 0.5-mg standard reference tablet.

摘要

相似文献

1
The assessment of the intrasubject variability in digoxin absorption in man from two oral dosage forms.
J Clin Pharmacol. 1981 Jul;21(7):301-10. doi: 10.1002/j.1552-4604.1981.tb01771.x.
2
A comparison of the bioavailability of digoxin in capsule, tablet, and solution taken orally with intravenous digoxin.口服地高辛胶囊、片剂和溶液与静脉注射地高辛的生物利用度比较。
J Clin Pharmacol. 1976 Oct;16(10 Pt 1):461-7.
3
A completely absorbed oral preparation of digoxin.
Clin Pharmacol Ther. 1976 Jun;19(6):746-51. doi: 10.1002/cpt1976196746.
4
Variability of steady-state digoxin kinetics during administration of tablets or capsules.
Clin Pharmacol Ther. 1986 Mar;39(3):306-12. doi: 10.1038/clpt.1986.44.
5
Absorption of digoxin from a new microencapsulated formulation.地高辛从一种新型微囊化制剂中的吸收情况。
Eur J Clin Pharmacol. 1980 Jun;17(6):443-7. doi: 10.1007/BF00570162.
6
Greater bioavailability of digoxin solution in capsules. Studies in the postprandial state.
Clin Pharmacol Ther. 1977 Mar;21(3):278-82. doi: 10.1002/cpt1977213278.
7
Digoxin bioavailability: formulations and rates of infusions.地高辛生物利用度:制剂与输注速率
Clin Pharmacol Ther. 1976 Sep;20(3):253-9. doi: 10.1002/cpt1976203253.
8
Superior bioavailability of digoxin solution in capsules.
Clin Pharmacol Ther. 1975 Dec;18(6):761-8. doi: 10.1002/cpt1975186761.
9
An improvement in digoxin bioavailability. Studies with soft gelatin capsules containing a solution of digoxin.
Arzneimittelforschung. 1979;29(7):1047-50.
10
Bioavailability of digoxin capsules and tablets: effect of coadministered fluid volume.
J Pharm Sci. 1984 Oct;73(10):1397-400. doi: 10.1002/jps.2600731018.

引用本文的文献

1
In Vitro-in Vivo Correlation: An Unrealistic Problem.体外-体内相关性:一个不切实际的问题。
Pharm Res. 1985 May;2(3):97-107. doi: 10.1023/A:1016355114960.
2
Comparison of the in vitro and in vivo release of digoxin from four different soft gelatin capsule formulations.
J Pharmacokinet Biopharm. 1979 Apr;7(2):147-58. doi: 10.1007/BF01059735.
3
Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension.在重复单次口服两片200毫克片剂和400毫克混悬液后CGP 33101的受试者内和受试者间变异性。
Pharm Res. 1995 Dec;12(12):1878-82. doi: 10.1023/a:1016275402723.
4
The pharmacokinetics of cefixime in the fasted and fed state.
Eur J Clin Pharmacol. 1988;34(5):525-8. doi: 10.1007/BF01046715.
5
Intra- and intersubject variability: mixed-effects statistical analysis of repeated doses of an angiotensin converting enzyme inhibitor, CGS 16617.个体内和个体间变异性:血管紧张素转换酶抑制剂CGS 16617重复给药的混合效应统计分析
Pharm Res. 1989 Apr;6(4):328-31. doi: 10.1023/a:1015954609527.
6
Bioavailability estimation by semisimultaneous drug administration: a Monte Carlo simulation study.通过半同步给药进行生物利用度估计:蒙特卡罗模拟研究
J Pharmacokinet Biopharm. 1990 Apr;18(2):103-20. doi: 10.1007/BF01063554.